Primary Hyperoxaluria (PH): A Patient Guide

Primary Hyperoxaluria (PH) is a rare, inherited condition that changes the way the liver processes metabolic waste. While the most visible symptoms—such as painful kidney stones—happen in the kidneys, the root of the problem is actually in the liver. In a person with PH, the liver lacks a specific enzyme needed to break down a compound called glyoxylate. Instead of being processed normally, this waste is converted into a substance called oxalate, which the liver then overproduces ^[1][2].

Because the kidneys are responsible for filtering oxalate out of the blood and into the urine, they become the primary organ affected by this overproduction. In the kidneys, the excess oxalate quickly binds with calcium to form hard crystals. These crystals can clump together to form stones, or they can deposit directly into the kidney tissue itself, a process called nephrocalcinosis. Over time, this constant crystallization can lead to scarring and a gradual decline in kidney function. If the kidneys become so damaged that they can no longer clear the oxalate, the substance begins to build up in the bloodstream and deposit in other organs—such as the heart, bones, and eyes—a serious complication known as systemic oxalosis ^[3][2].

Living with PH requires a dedicated, “round-the-clock” approach to care. The most essential daily protection is intensive hydration—maintaining a clinician-prescribed fluid intake to keep the urine diluted. This hydration lowers the risk of stone formation but does not guarantee crystals cannot form, so it is often paired with crystallization inhibitors, like citrate. For a subset of patients with PH1, high doses of Vitamin B6 (pyridoxine) can help the liver’s enzymes work more efficiently, though this requires specialist monitoring for potential toxicity. Because the liver’s “factory” never stops, these treatments must be maintained consistently, even during the night ^[4][5].

The landscape of PH treatment is changing rapidly with the arrival of advanced therapies. Newer medicines known as RNA interference (RNAi) therapies, such as lumasiran and nedosiran, work by “silencing” the specific signals in the liver that lead to oxalate production. Eligibility for these treatments is highly dependent on subtype, genotype, kidney function, age, and jurisdiction. Because PH is a genetic condition, family screening is a vital part of the diagnosis process. Siblings of a person with PH may have the condition without showing any outward signs, and finding it early through targeted genetic testing can allow for protective treatments to start before significant kidney damage occurs ^[6][7].